Last reviewed · How we verify
NCT06650098
Artificial Intelligence-Supported Mobile Application For Diabetes Self-Management
NA trial testing artificial intelligence-supported mobile application in Diabetes Mellitus in 156 participants. Not yet recruiting.
1 January 2026
Quick facts
| Lead sponsor | Uludag University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 156 |
| Start date | 1 April 2025 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- artificial intelligence-supported mobile application
- WEB based application
Conditions studied
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
- Artificial Intelligence (AI) — all drugs for Artificial Intelligence (AI) →
- Self-management — all drugs for Self-management →
Sponsor
Uludag University
Who can join
Eligibility, any sex, with Diabetes Mellitus or Artificial Intelligence (AI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients in the AI-supported mobile application group will be able to log in with a username and password that will be defined specifically for them. Patients will be informed about how the application is used during their first interview. They will enter their personal and disease characteristics (age, gender, height, weight, HbA1C, HDL, LDL) into the application at the entrance. Other sections of the application will include exercise, nutrition, medication tracking, complication tracking and diabetic foot care sections. The person will be asked to enter relevant information in these fields according to their own life and condition (for example; how many times do you use insulin per day, what are your medication times, how do you spend your day in terms of exercise, how many meals do you eat, what is your diet, do you urinate frequently, are you extremely thirsty, are you hungry often, do you have numbness in your hands and feet, etc.). After the patient enters the necessary information, they will also be asked to enter their daily blood sugar measurement values into the system. Thus, the individual\'s hypo/hyperglycemia risk, risk analysis, nutrition recommendations, medication reminder system, exercise reminder and incentive warnings will be communicated to the individual thanks to the AI-based mobile application. The aim of this application is to reduce the risk of complications and improve the individual\'s quality of life by providing personalized recommendations for all the needs of the individual, including alarms and reminders, and to support patients to continue their diabetes education and disease management more actively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06650098
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
- NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
- NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting
Other Uludag University trials
Trials by the same sponsor.
- NCT07478601 — Effect of Erector Spinae Plane Block on Postoperative Respiratory Function After Laparoscopic Cholecystectomy · NA · not yet recruiting
- NCT07440615 — Lower-Limb Muscle Mass and Cardiovascular and Muscular Performance in Males and Females · NA · not yet recruiting
- NCT07393620 — Predictive Value of aEEG and Cerebral Oxygenation on Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Enceph · not yet recruiting
- NCT07350018 — Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome · Phase 4 · not yet recruiting
- NCT07365605 — Lower-Limb Muscle Mass and Balance Performance · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06650098 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uludag University
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06650098.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing